prikaz prve stranice dokumenta Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
  Preuzmi
PDF 3.15 MB
Znanstveni rad - Izvorni znanstveni rad
Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
Diabetology, 5 (2024), 1; 26-39. https://doi.org/10.3390/diabetology5010003
Matovinović, Martina; Belančić, Andrej; Jug, Juraj; Mustač, Filip; Sirovica, Maja; Santini, Mihovil; Bošnjaković, Anja; Lovrić, Mario; Lovrić Benčić, Martina

Citirajte ovaj rad

Matovinović, M., Belančić, A., Jug, J., Mustač, F., Sirovica, M., Santini, M. ... Lovrić Benčić, M. (2024). Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?. Diabetology, 5. (1), 26-39. doi: 10.3390/diabetology5010003

Matovinović, Martina, et al. "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?." Diabetology, vol. 5, br. 1, 2024, str. 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, Martina, Andrej Belančić, Juraj Jug, Filip Mustač, Maja Sirovica, Mihovil Santini, Anja Bošnjaković, Mario Lovrić i Martina Lovrić Benčić. "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?." Diabetology 5, br. 1 (2024): 26-39. https://doi.org/10.3390/diabetology5010003

Matovinović, M., et al. (2024) 'Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?', Diabetology, 5(1), str. 26-39. doi: 10.3390/diabetology5010003

Matovinović M, Belančić A, Jug J, Mustač F, Sirovica M, Santini M, i sur.. Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?. Diabetology [Internet]. 04.01.2024. [pristupljeno 17.06.2024.];5(1):26-39. doi: 10.3390/diabetology5010003

M. Matovinović, et al., "Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?", Diabetology, vol. 5, br. 1, str. 26-39, Siječanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:769094. [Citirano: 17.06.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:769094
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
AutorMartina Matovinović
AutorAndrej Belančić
AutorJuraj Jug
AutorFilip Mustač
AutorMaja Sirovica
AutorMihovil Santini
AutorAnja Bošnjaković
AutorMario Lovrić
AutorMartina Lovrić Benčić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background: Diabetes is the primary contributor to cardiovascular disease risk, and when combined with obesity, it further underscores the significance of cardiovascular risk assessment. Methods: A retrospective study of 64 patients with type 2 diabetes (T2D) and obesity on once-weekly subcutaneous semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes, and ASCVD score calculations. We compare the differences between groups (ASCVD: low + borderline + intermediate versus high-risk group; SCORE2/SCORE2-OP: low + moderate versus high + very high-risk group and SCORE2-Diabetes: low + moderate versus high + very high-risk group) in terms of change from baseline in body mass index (BMI) and HbA1c and weight loss outcomes. Results: Patients in the high-risk group, according to ASCVD risk score, had statistically better results in weight loss ≥ 3%, ≥5%, and ≥10% compared to ASCVD low + borderline + intermediate and without difference regarding HbA1c. According to SCORE2/SCORE2-OP, the high + very high-risk group had statistically better HbA1c and weight loss results but only for ≥5% versus the low + moderate risk group. Based on the score SCORE2-Diabetes, the high + very high-risk group had statistically significant better results in lowering HbA1c and weight loss but only for ≥5% versus the low + moderate risk group. Conclusions: To the best of our knowledge, this study represents the initial investigation linking glycemic control and weight reduction outcomes in individuals with T2D and obesity treated with once-weekly semaglutide stratified by cardiovascular risk categories determined using the SCORE2/SCORE2-OP, SCORE2-Diabetes and ASCVD score calculations.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDiabetology
Brojčani podacivol. 5, br. 1, str. 26-39
e-ISSN2673-4540
DOIhttps://doi.org/10.3390/diabetology5010003
URN:NBNurn:nbn:hr:184:769094
Datum objave publikacije2024-01-04
URL dokumentahttps://www.mdpi.com/2673-4540/5/1/3
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-01-05 12:24:56